Somatostatin, tau, and β-amyloid within the anterior olfactory nucleus in Alzheimer disease

Experimental Neurology

Volumn 223, Issue 2, 2010, Pages 347-350

  Saiz Sanchez, D ^a   Ubeda Banon I ^a   de la Rosa Prieto, C ^a   Argandona Palacios L ^b   Garcia Munozguren S ^b   Insausti, R ^a   Martinez Marcos, A ^a  

^a University of Castilla La Mancha   (Spain)

^b HOSPITAL GENERAL UNIVERSITARIO DE ALBACETE   (Spain)

Author keywords

amyloid; Alzheimer disease; Anterior olfactory nucleus; Human brain; Neprilysin; Olfactory deficits; Somatostatin; Tau

Indexed keywords

AMYLOID BETA PROTEIN; SOMATOSTATIN; TAU PROTEIN;

ADULT; AGED; ALZHEIMER DISEASE; ARTICLE; BRAIN LEVEL; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOFLUORESCENCE; MALE; OLFACTORY NUCLEUS; PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN EXPRESSION; PROTEIN LOCALIZATION;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN; FEMALE; FLUORESCENT ANTIBODY TECHNIQUE; HUMANS; MALE; MIDDLE AGED; NEPRILYSIN; OLFACTION DISORDERS; OLFACTORY BULB; SOMATOSTATIN; TAU PROTEINS;

EID: 77952552363     PISSN: 00144886     EISSN: 10902430     Source Type: Journal    
DOI: 10.1016/j.expneurol.2009.06.010     Document Type: Article

References (28)

1. Braak H., Braak E. Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol. 1991, 82:239-259.
2. Burgos-Ramos E., Hervas-Aguilar A., Aguado-Llera D., Puebla-Jimenez L., Hernandez-Pinto A.M., Barrios V., Arilla-Ferreiro E. Somatostatin and Alzheimer's disease. Mol. Cell. Endocrinol. 2008, 286:104-111.
3. Davies P., Katzman R., Terry R.D. Reduced somatostatin-like immunoreactivity in cerebral cortex from cases of Alzheimer disease and Alzheimer senile dementa. Nature 1980, 288:279-280.
4. Djordjevic J., Jones-Gotman M., De Sousa K., Chertkow H. Olfaction in patients with mild cognitive impairment and Alzheimer's disease. Neurobiol. Aging 2008, 29:693-706.
5. Doty R.L. Olfactory capacities in aging and Alzheimer's disease. Psychophysical and anatomic considerations. Ann. N.Y. Acad. Sci. 1991, 640:20-27.
6. Doty R.L. Odor perception in neurodegenerative diseases. Handbook of Olfaction and Gustation 2003, 479-501. Marcel Dekker, New York. R.L. Doty (Ed.).
7. Doty R.L., Perl D.P., Steele J.C., Chen K.M., Pierce J.D., Reyes P., Kurland L.T. Olfactory dysfunction in three neurodegenerative diseases. Geriatrics 1991, 46(Suppl 1):47-51.
8. Epelbaum J. Somatostatin in the central nervous system: physiology and pathological modifications. Prog. Neurobiol. 1986, 27:63-100.
9. Ferrier I.N., Leake A. Peptides in the neocortex in Alzheimer's disease and ageing. Psychoneuroendocrinology 1990, 15:89-95.
10. Gillies G. Somatostatin: the neuroendocrine story. Trends Pharmacol. Sci. 1997, 18:87-95.
11. Guillery R.W. On counting and counting errors. J. Comp. Neurol. 2002, 447:1-7.
12. Hama E., Saido T.C. Etiology of sporadic Alzheimer's disease: somatostatin, neprilysin, and amyloid beta peptide. Med. Hypotheses 2005, 65:498-500.
13. Hardy J.A., Higgins G.A. Alzheimer's disease: the amyloid cascade hypothesis. Science 1992, 256:184-185.
14. Hawkes C.H., Doty R.L. The Neurology of Olfaction 2009, Cambridge University Press, Cambridge.
15. Hughes L.F., Struble R.G., Shaffer C.L. Olfaction in elderly and patients with Alzheimer's disease: differing feedback conditions. J. Alzheimer's Dis. 2001, 3:367-375.
16. Iwata N., Higuchi M., Saido T.C. Metabolism of amyloid-beta peptide and Alzheimer's disease. Pharmacol. Ther. 2005, 108:129-148.
17. Koss E., Weiffenbach J.M., Haxby J.V., Friedland R.P. Olfactory detection and identification performance are dissociated in early Alzheimer's disease. Neurology 1988, 38:1228-1232.
18. Lu T., Pan Y., Kao S.Y., Li C., Kohane I., Chan J., Yankner B.A. Gene regulation and DNA damage in the ageing human brain. Nature 2004, 429:883-891.
19. Mount C., Downton C. Alzheimer disease: progress or profit?. Nat. Med. 2006, 12:780-784.
20. Ohm T.G., Braak H. Olfactory bulb changes in Alzheimer's disease. Acta Neuropathol. 1987, 73:365-369.
21. Price J.L. Olfactory system. The Human Nervous System 1990, 979-998. Academic Press, San Diego. G. Paxinos (Ed.).
22. Price J.L., Morris J.C. So what if tangles precede plaques?. Neurobiol. Aging 2004, 25:721-723. discussion 743-726.
23. Price J.L., Davis P.B., Morris J.C., White D.L. The distribution of tangles, plaques and related immunohistochemical markers in healthy aging and Alzheimer's disease. Neurobiol. Aging 1991, 12:295-312.
24. Saido T.C., Iwata N. Metabolism of amyloid beta peptide and pathogenesis of Alzheimer's disease. Towards presymptomatic diagnosis, prevention and therapy. Neurosci. Res. 2006, 54:235-253.
25. Saito T., Iwata N., Tsubuki S., Takaki Y., Takano J., Huang S.M., Suemoto T., Higuchi M., Saido T.C. Somatostatin regulates brain amyloid beta peptide Abeta42 through modulation of proteolytic degradation. Nat. Med. 2005, 11:434-439.
26. Selkoe D.J. Alzheimer's disease: genes, proteins, and therapy. Physiol. Rev. 2001, 81:741-766.
27. van de Nes J.A., Konermann S., Nafe R., Swaab D.F. Beta-protein/A4 deposits are not associated with hyperphosphorylated tau in somatostatin neurons in the hypothalamus of Alzheimer's disease patients. Acta Neuropathol. 2006, 111:126-138.
28. Viollet C., Lepousez G., Loudes C., Videau C., Simon A., Epelbaum J. Somatostatinergic systems in brain: networks and functions. Mol. Cell. Endocrinol. 2008, 286:75-87.